TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05841745

Intervention type: DEVICE
Intervention: Robotically-Assisted Percutaneous Coronary Intervention with CorPath GRX System
Description: The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary and vascular procedures. The CorPath GRX System is composed of two units; the first is a bedside unit which consists of the extended robotic arm, robotic drive, and single-use loading cassette, and the second is the remote workstation, which consists of the interventional cockpit and the control console. A key innovation of the CorPath GRX System is the software-based automation of common maneuvers, called technIQ automated movements with the potential to increase procedural success, reduce procedure time, and generally increase user comfort with robotic assistance during PCI.
Study: NCT04779957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered at 8 mg/kg before or immediately after graft nephrectomy.
Study: NCT05191706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: single anterior chamber injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate Ophthalmic
Description: topical administration four times a day for 28 days, followed by treatment taper
Study: NCT05180630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audeo P90 hearing aid with custom earmolds using dynamic venting
Description: Audeo P90 hearing aids coupled to custom earmolds that use dynamic venting.
Study: NCT06538532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zamzam water
Description: Zamzam water
Study: NCT05180630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audeo P90 hearing aid with custom earmolds using dynamic venting
Description: Audeo P90 hearing aids coupled to custom earmolds that use dynamic venting.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audeo P90 hearing aid with custom earmolds using dynamic venting
Description: Audeo P90 hearing aids coupled to custom earmolds that use dynamic venting.
Study: NCT06559397

Intervention type: OTHER
Intervention: Assessment of cervical proprioception
Description: Cervical proprioception will be assessed using the 'head position error test' in both right and left rotation directions with the CROM device. Participants will be then divided into two groups based on the presence of proprioceptive errors (\>5°).

Intervention type: OTHER
Intervention: Assessment of cervical proprioception
Description: Cervical proprioception will be assessed using the 'head position error test' in both right and left rotation directions with the CROM device. Participants will be then divided into two groups based on the presence of proprioceptive errors (\>5°).
Study: NCT05101564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Alpelisib 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Tamoxifen 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zotatifin
Description: Zotatifin 0.10mg/kg (by weight)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zotatifin
Description: Zotatifin 0.10mg/kg (by weight)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zotatifin
Description: Zotatifin 0.10mg/kg (by weight)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zotatifin
Description: Zotatifin 0.10mg/kg (by weight)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zotatifin
Description: Zotatifin 0.10mg/kg (by weight)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zotatifin
Description: Zotatifin 0.10mg/kg (by weight)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant 500 mg
Study: NCT05180630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audeo P90 hearing aid with Open domes
Description: Audeo P90 hearing aid coupled with non-custom, manufacturer open domes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audeo P90 hearing aid with Open domes
Description: Audeo P90 hearing aid coupled with non-custom, manufacturer open domes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audeo P90 hearing aid with Open domes
Description: Audeo P90 hearing aid coupled with non-custom, manufacturer open domes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audeo P90 hearing aid with Vented domes
Description: Audeo P90 hearing aid coupled with non-custom, manufacturer vented domes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audeo P90 hearing aid with Vented domes
Description: Audeo P90 hearing aid coupled with non-custom, manufacturer vented domes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audeo P90 hearing aid with Vented domes
Description: Audeo P90 hearing aid coupled with non-custom, manufacturer vented domes
Study: NCT04730544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 480mg + Ipilimumab
Description: Nivolumab 480 mg q4w + Ipilimumab 1 mg/kg q6w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab 240 mg + Ipilimumab
Description: induction phase : Nivolumab 240 mg q3w + Ipilimumab 1 mg/kg q3w and then maintenance : Nivolumab 480 mg q4w
Study: NCT05145660

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity-modulated radiotherapy (IMRT) with reduced-volume
Description: PGTVnx: 69.9Gy/2.12Gy/33f GTVrpn: 69.9Gy/2.12Gy/33f GTVnd: 69.9Gy/2.12Gy/33f GTVnd-suspicious: 60.06Gy/1.82Gy/33f PTV1: 60.06Gy/1.82Gy/33f PTV2: 50.96Gy/1.82Gy/28f

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiotherapy (IMRT) with reduced-volume
Description: PGTVnx: 69.9Gy/2.12Gy/33f GTVrpn: 69.9Gy/2.12Gy/33f GTVnd: 69.9Gy/2.12Gy/33f GTVnd-suspicious: 60.06Gy/1.82Gy/33f PTV1: 60.06Gy/1.82Gy/33f PTV2: 50.96Gy/1.82Gy/28f

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Concurrent cisplatin (100 mg/m², d1-3, Q3w, maximum to three cycles); The application of induction chemotherapy and consolidation chemotherapy is dependent on the physician's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Concurrent cisplatin (100 mg/m², d1-3, Q3w, maximum to three cycles); The application of induction chemotherapy and consolidation chemotherapy is dependent on the physician's discretion.
Study: NCT05101564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500 mg
Study: NCT04788147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RMRS IDE Device
Description: Participants will be injected with FDG at the studied dose and will undergo imaging sessions using the RMRS IDE device and a third-party Positron Emission Tomography (PET)/CT imaging device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RMRS IDE Device
Description: Participants will be injected with FDG at the studied dose and will undergo imaging sessions using the RMRS IDE device and a third-party Positron Emission Tomography (PET)/CT imaging device.
Study: NCT05193331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Diquafosol tetrasodium
Description: 3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
Study: NCT04636892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MindMics earbud
Description: Novel noninvasive wearable infrasound sensor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MindMics earbud
Description: Novel noninvasive wearable infrasound sensor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MindMics earbud
Description: Novel noninvasive wearable infrasound sensor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MindMics earbud
Description: Novel noninvasive wearable infrasound sensor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MindMics earbud
Description: Novel noninvasive wearable infrasound sensor
Study: NCT06294002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic neuromuscular stabilisation group
Description: DNS group protocol involved 5 min a moderate intensity warm-up, 40 minutes of DNS movements according to the DNS approach, different diaphragmatic breathing, mobility and controlled movement exercises and 5 minutes of cool-down. Exercises gradually increased in complexity and difﬁculty level regarding DNS training principles. The participants were instructed to refrain from engaging in high-intensity anaerobic or anaerobic resistance training throughout the study period to prevent potential disruptions in the study results.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration group
Description: WBV was performed on the Power Plate Next Generation vibration platform (Power Plate North America, Chicago, IL). All training routines were approximately 50 minutes long, commencing with 5 minutes of moderate-intensity warm-up and concluding with a cool-down period. The program consisted of 8-10 static and dynamic exercises for PS that progressively increased in difficulty and complexity. During the training process, the frequency increased from 20 to 35 Hz in the last week of the experiment; the exercise duration was from 20 - 60 seconds (in the previous week), followed by 1-minute seated rest. Moreover, the complexity and difficulty of exercise increased over the experimental period. The resting period between sets was constant from the start to the end of the training process. During the experiment, the WBV intervention group performed three weekly training sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic neuromuscular stabilisation with whole body vibration group
Description: The MIX group underwent a two-month training program consisting of three weekly sessions, including a 50-minute exercise program with a 5-minute warm-up and cool-down period. The training included 20 minutes of WBV and 20 minutes of DNS training, following previous research and training recommendations. VIBRO exercises were performed on the Power Plate Next Generation vibration platform, with 6-8 exercises for balance and PS. Participants were advised not to engage in high-intensity anaerobic or anaerobic resistance training. The training protocol was adapted from previous research.
Study: NCT06542068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Line Bot Assistance
Description: The chatbot is expected to provide self-help solutions and multiple counseling resources for stress and distress, options for face-to-face or online call requests, and a survey on mental health and stress.~In terms of keywords, it will establish counseling response resources and methods for finding resources for special sensitive situations (e.g., feeling moody, suicidal, stressed, not wanting to intern, etc.).
Study: NCT06065696

Intervention type: PROCEDURE
Intervention: Early mobilization
Description: Patients who received early mobilization in postoperative period
Study: NCT06123975

Intervention type: OTHER
Intervention: Venous blood collection
Description: Peripheral blood was collected on the day of embryo transfer. And if the pregnancy test was positive at 14 days after embryo transfer, peripheral blood was collected at 21 days after the transfer and every 2 weeks thereafter until 12 weeks of gestation.
Study: NCT06065696

Intervention type: PROCEDURE
Intervention: No early mobilization
Description: Patients who did not receive early mobilization in postoperative period
Study: NCT06189300

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education and counseling intervention
Description: In addition to standard training, training and consultancy will be provided to individuals with stoma intermittently within a month.
Study: NCT05988827

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NGenuity
Description: Cataract surgery performed under microscope using NGenuity
Study: NCT05935228

Intervention type: OTHER
Group type: OTHER
Intervention: Implementation of the A-DIVA Scale
Description: Phase 2 aims to evaluate the impact of the implementation of the A-DIVA Scale (classification score for difficult intravenous access) on practitioners' approaches to the peripheral venous catheter placement. It consists of a systematic collection of peripheral venous catheter placement practices for quantitative data and a questionnaire of professionals' opinions on the use of the A-DIVA scale for qualitative data. The main objective of this phase is to recognize the potential appearance of changes in practices through the implementation of a tool for evaluating vascular access difficulties

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of the algorithm composed of the A-DIVA Scale and the new decision-making tree (the A-DIVA Tool) in the centers
Description: The main objective of this phase is to evaluate the impact of the algorithm on the quality of peripheral venous catheter placement.~• Systematic collection of judgment criteria and socio-demographic and clinical characteristics of patients. Description of the care strategy implemented. Systematic collection of the A-DIVA Scale with identification of the patient's risk group, systematic rating of pain and evaluation of overall comfort.
Study: NCT04959708

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insula treatment
Description: he intervention will consist of twelve individual treatments. Insula method consists of the facilitation and activation of self-regulation resources, relational regulation through breathing, movement, contact, sensory stimulation and posture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insula treatment
Description: he intervention will consist of twelve individual treatments. Insula method consists of the facilitation and activation of self-regulation resources, relational regulation through breathing, movement, contact, sensory stimulation and posture
Study: NCT05723042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMS with CIMT
Description: The interventions are consisted of 3weeks of casting the unaffected limb followed by 5 weeks of transference activities.The assisting hand assessment AHA was used to measure bimanual activity performance at baseline,8 weeks, 16 weeks. 20-minute application of currents and resistance exercises for the respective muscles of the area. The intervention group with 11 patients underwent a program of CIMT for one hour daily for 14 consecutive days or two hours per day, six days per week and a total of 12 weeks. A follow-up will be performed 12 weeks after the intervention. The healthy upper limb will be immobilized by orthosis or cast for six hours a day . Electrotherapy will be applied with TENS for 15 minutes at intervals of 1000ms and with a pulse duration of 50ms. The square wave will be chosen to ensure that there will be sufficient muscle contraction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EMS
Description: this group will only receive baseline exercises (ROM and flexibility exercises) than apply electrical stimulations at specific motor points. Electrotherapy will be applied with TENS for 15 minutes at intervals of 1000ms and with a pulse duration of 50ms. The square wave will be chosen to ensure that there will be sufficient muscle contraction
Study: NCT06566287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate implant
Description: Immediate Implant with Socket Shield Group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed implant
Description: Delayed Implant with Socket preserved with socket Shield and dentin graft Group
Study: NCT06567483

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ELISIO21HX
Description: Super-high flux dialyzers (ELISIO21HX) will be used. The blood flow rate and dialysate flow rate will be set as 400 and 800 ml/min respectively for 4 hours of dialysis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELISIO21HX
Description: Super-high flux dialyzers (ELISIO21HX) will be used. The blood flow rate and dialysate flow rate will be set as 400 and 800 ml/min respectively for 4 hours of dialysis.
Study: NCT06560996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low calorie diet with low protein content (VLCD-LP group)
Description: Very low calorie diet (850 kcals per day) with low protein content (10%)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low calorie diet with high protein content (VLCD-HP group)
Description: Very low calorie diet (850 kcals per day) with high protein content (30%)
Study: NCT05764837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foam Rolling
Description: Foam rolling was performed for 4 minutes with the goal of affecting the entire myofascial posterior chain.
Study: NCT04880941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Relaxation Exercise
Description: In the progressive relaxation technique, the tension and anxiety in skeletal muscles are relatively relieved.
Study: NCT05623709

Intervention type: DEVICE
Intervention: Positive airway pressure with continuous positive airway pressure or noninvasive ventilation
Description: CPAP or NIV prescribed by the treating respirologist for long-term use at home
Study: NCT06531668

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beyond Hormone
Description: Participants will take three capsules once daily with their morning meal for the duration of three menstrual cycles.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take three capsules once daily with their morning meal for the duration of three menstrual cycles.
Study: NCT05758662

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-sodium fluoride Positron Emission Tomography (18F-NaF PET), Cardiac Computed Tomography (CT), Transthoracic Echocardiography (TTE)
Description: Patients undergo a hybrid 18F-NaF-PET CT scan and TTE at five years after TAVI
Study: NCT05669924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 0.35 mg/kg methylphenidate will be administered after baseline testing and 45 min-1 hr before post-intervention testing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for methylphenidate
Study: NCT05643118

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)
Description: Clear colorless solution dissolved in 1X PBS and injected intravitreally

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)
Description: Clear colorless solution dissolved in 1X PBS and injected intravitreally

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)
Description: Clear colorless solution dissolved in 1X PBS and injected intravitreally

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)
Description: Clear colorless solution dissolved in 1X PBS and injected intravitreally

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)
Description: Clear colorless solution dissolved in 1X PBS and injected intravitreally

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)
Description: Clear colorless solution dissolved in 1X PBS and injected intravitreally

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)
Description: Clear colorless solution dissolved in 1X PBS and injected intravitreally
Study: NCT06541743

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular Toothbrush
Description: Participants and their guardians will be instructed in the horizontal scrub technique and asked to adhere to a brushing regimen of two minutes, twice daily, for 45 days. Standard fluoride toothpaste and a diary for recording brushing experiences will also provided. Guardians will be supervised brushing to ensure compliance and prevent the use of other oral hygiene measures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Musical toothbrush
Description: Participants and their guardians will be instructed in the horizontal scrub technique and asked to adhere to a brushing regimen of two minutes, twice daily, for 45 days. Standard fluoride toothpaste and a diary for recording brushing experiences will also provided. Guardians will be supervised brushing to ensure compliance and prevent the use of other oral hygiene measures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electric toothbrush
Description: Participants and their guardians will be instructed in the horizontal scrub technique and asked to adhere to a brushing regimen of two minutes, twice daily, for 45 days. Standard fluoride toothpaste and a diary for recording brushing experiences will also provided. Guardians will be supervised brushing to ensure compliance and prevent the use of other oral hygiene measures.
Study: NCT05390489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cascara pulp arabica gayo coffee cream
Description: extract of cascara pulp arabica gayo coffee
Study: NCT05893108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethosomal gel bearing losartan 5%
Description: A pharmaceutical company with a good manufacturing practice certificate is developing ethosomal gel bearing losartan 5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone acetonide 10 mg/ml
Description: intralesional injection